Sanofi is rebuilding itself into an AI-powered specialty-biopharma cash compounder—yet the market prices it like Dupixent and U.S. pricing reform will break the model.
Overview
Sanofi is completing a major transformation into a focused, specialty-biopharma company with a stronger balance sheet and a heavier emphasis on AI-enabled R&D productivity. The April 2025 sale of a 50% controlling stake in its Consumer Healthcare unit (Opella) to CD&R at ~€16B EV (~14x 2024E EBITDA) generated ~€10B net cash while Sanofi retained a 48.2% stake, preserving upside participation as Opella operates independently. Post-divestment, Sanofi’s revenue is concentrated in high-margin Specialty Care, General Medicines, and Vaccines, with the U.S. as the key profit pool. Growth is anchored by Dupixent’s broadening immunology dominance (2025 sales €15.7B) and accelerating new launches (e.g., ALTUVIIIO, Beyfortus), supported by M&A and AI integration via its Plai platform. Against this, Sanofi faces an unusually complex risk matrix: U.S. MFN pricing reforms that force sharp unit price deflation and a direct-to-patient model shift, an approaching Dupixent patent cliff (U.S. Dec-2028), and a high-stakes CEO transition from Paul Hudson to Belén Garijo in 2026—making the stock a cash-rich but policy- and pipeline-sensitive value proposition.